Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the...

Related Keywords

United States ,Texas ,Massachusetts ,Athlone ,Westmeath ,Ireland ,Waltham ,Ohio ,Dublin ,Michigan ,Cincinnati ,Kenilworth ,Chicago ,Illinois ,American ,Sarinaa Piha Paul ,Thomasj Herzog ,Craig Hopkinson ,Jill Odonnell Tormey ,Jeffreys Weber ,Los Angeles ,Omid Hamid ,Ulkan Vaishampayan ,Sandy Coombs ,Sourojit Bhowmick ,Division Of Cancer Medicine ,American Society Of Clinical Oncology ,Isaac Perlmutter Cancer Center ,Cancer Research Institute ,Research Development At Alkermes ,Research Development ,Nasdaq ,University Of Michigan ,Merck Co Inc ,York University School Of Medicine ,Department Of Investigational Cancer Therapeutics ,Translational Research ,Alkermes ,Phasei Program ,University Of Cincinnati Cancer Institute ,University Of Texas Md Anderson Cancer Center ,Clinical Development Program ,Merck Sharp Dohme Corp ,Exchange Commission ,Division Of Hematology Oncology ,Research Institute ,Company To Host Investor Webcast On ,Scientific Affairs ,Showed Anti Tumor Activity ,Multiple Tumor Types ,Host Investor Webcast ,Clinical Oncology ,Annual Meeting ,Internal Medicine ,Chief Medical Officer ,Executive Vice President ,Combination With Pembrolizumab ,Jillo Donnell Tormey ,Chief Executive Officer ,Cancer Research ,Deputy Director ,Cincinnati Cancer Institute ,Associate Director ,Associate Professor ,Investigational Cancer Therapeutics ,Cancer Medicine ,New York University School ,Cutaneous Oncology ,Melanoma Therapeutics ,Phasei Immuno Oncology Program ,Angeles Clinic ,Cedars Sinai Affiliate ,Deputy Director University ,Nemvaleukin Alfa ,Private Securities Litigation Reform Act ,Annual Report ,Merck Sharp ,Dohme Corp ,Alkermes Plc ,